IDEAYA Biosciences (NASDAQ:IDYA) promoted Paul Stone to CFO, Andres Briseno to VP finance, and Mick O’Quigley to VP development operations.
Continuing his role as IDEAYA’s principal financial and accounting officer, as well as its general counsel, Mr. Stone will also lead the company’s finance, investor relations, and public relations functions as CFO. Mr. Stone was previously with 5AM Ventures and held management and operating roles in the companies it launched, including IDEAYA, Homology Medicines, Cidara Therapeutics, and Entrada Therapeutics.
Mr. Briseno most recently served as IDEAYA’s senior director of finance and controller. He was previously associate director of financial planning and analysis at Pharmacyclics, and earlier held roles at Theravance and PricewaterhouseCoopers.
Mr. O’Quigley has contributed to IDEAYA’s clinical operations and alliance, data and project management. He joined IDEAYA with more than 20 years of clinical operations experience, and was most recently program group director, cancer immunotherapy portfolio at Genentech, where he led global clinical operations activities for 10 years.
“These appointments within our management team are critical as we advance our lead oncology program, IDE196, in our GNAQ/GNA11 tissue-type agnostic basket trial, and continue to build our leading precision medicine oncology pipeline, including IDEAYA’s MAT2A synthetic lethality program to treat MTAP-deletion patients,” Yujiro Hata, IDEAYA’s president and CEO, said in a statement.
